Opicapone is a novel third generation catechol-O-methyltransferase (COMT) inhibitor, providing potent and sustained COMT inhibition. This action enhances the beneficial effects of levodopa in Parkinson’s disease patients with motor fluctuations. Opicapone is supported by a large and comprehensive clinical development programme. Data from the pivotal studies BIPARK I and II has been presented at various international scientific congresses. The Opicapone EU marketing authorization application has been successfully validated and is now under review by the European Medicines Agency (EMA).
Parkinson's disease is a degenerative disorder of the central nervous system characterized by bradykinesia (slowness of movement), tremor, muscle rigidity and postural instability. The clinical manifestations usually start after the age of 50 years and the incidence increases with age. The prevalence is estimated at 300 per 100,000 inhabitants, increasing to 1/100 over the age of 55–60 years.
1. Ferreira JJ, Lees A, Rocha JF, Poewe W, Rascol O, Soares-da-Silva P; Bi-Park 1 investigators. Opicapone as an adjunct to levodopa in patients with Parkinson's disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial. Lancet Neurol. 2015 Dec 22. doi: 10.1016/S1474-4422(15)00336-1. [Epub ahead of print]
2. Rocha JF, Falcão A, Santos A, Pinto R, Lopes N, Nunes T, Wright LC, Vaz-da-Silva M, Soares-da-Silva P. Effect of opicapone and entacapone upon levodopa pharmacokinetics during three daily levodopa administrations. Eur J Clin Pharmacol. 2014 Sep;70(9):1059-71.
- Opicapone significantly improves OFF-time in fluctuating Parkinson’s Disease patients as add-on to levodopa
- BIAL licenses a new medicine for Parkinson
BIAL is member of the European Parkinson's Disease Association.